05.10.17
AMRI
1Q Revenues: $163.8 million (+55%)
1Q Loss: $10.7 million (loss of $10.1 million 1Q16)
Comments: Contract revenue for the quarter was $160.2 million, up 56%. Recurring royalty revenue in quarter was $3.6 million, an increase of 31%. Active Pharmaceutical Ingredients (API) revenues were $106.1 million, up from $57.1 million. Discovery, Development and Analytical Services (DDS) revenue was $29.2 million, up 24%. Drug Product (DP) revenue was $23.4 million, down 10% primarily due to timing of shipments and planned site maintenance activities. Fine Chemicals (FC) sales were $5.1 million. FC is a new reporting segment for AMRI resulting from the acquisition of Euticals in July 2016.
1Q Revenues: $163.8 million (+55%)
1Q Loss: $10.7 million (loss of $10.1 million 1Q16)
Comments: Contract revenue for the quarter was $160.2 million, up 56%. Recurring royalty revenue in quarter was $3.6 million, an increase of 31%. Active Pharmaceutical Ingredients (API) revenues were $106.1 million, up from $57.1 million. Discovery, Development and Analytical Services (DDS) revenue was $29.2 million, up 24%. Drug Product (DP) revenue was $23.4 million, down 10% primarily due to timing of shipments and planned site maintenance activities. Fine Chemicals (FC) sales were $5.1 million. FC is a new reporting segment for AMRI resulting from the acquisition of Euticals in July 2016.
